Luo Zhi-Fen, Zhou Yun, Liu Ming-Yue
Department of Oncology, Henan Provincial People's Hospital, Zhengzhou, Henan, 450003, PR China.
Ai Zheng. 2007 Aug;26(8):843-5.
BACKGROUND & OBJECTIVE: Some studies have showed that topoisomerase (Topo)I and II inhibitors have synergistic effects in tumor therapy, but the combinations have seldom been used in gastric cancer. This study was to investigate the effects of Topo I inhibitor hydroxycamptothecin (HCPT) and Topo II inhibitor teniposide (VM-26) on the proliferation and apoptosis of gastric cancer cell line BGC-823.
MTT assay was used to examine the inhibitory effects of VM-26 and HCPT, used alone or in combination, on the proliferation of BGC-823 cells. Cell apoptosis was examined by flow cytometry (FCM).
The inhibition rates of BGC-823 cell proliferation were 15.99%-80.83% when treated with 1.963-31.413 micromol/L VM-26; the apoptosis rates were 3.90%, 4.42%, 7.36%, 17.07% when exposed to 1.963 micromol/L VM-26 for 0, 12, 24, 48 h, respectively. The inhibition rates of BGC-823 cell proliferation were 7.89%-70.32% when treated with 8.577-137.227 micromol/L HCPT; the apoptosis rates were 2.80%, 8.50%, 10.50%, 13.30% when exposed to 8.577 micromol/L HCPT for 0, 12, 24, 48 h, respectively. When treated with 1.963 micromol/L VM-26 and 3.125 microg/ml HCPT for 0, 12, 24, 48 h, the inhibition rates of BGC-823 cell proliferation were 21.32%-87.74%, and the apoptosis rates were 2.80%, 15.50%, 15.70%, 20.20%, respectively. The combination index (CI) was 1.293.
HCPT and VM-26 used alone could inhibit the proliferation and induce the apoptosis of BGC-823 cells, and they have antagonistic effect on gastric cancer BGC-823 cells.
一些研究表明，拓扑异构酶（Topo）Ⅰ和Ⅱ抑制剂在肿瘤治疗中具有协同作用，但这些联合用药在胃癌治疗中很少使用。本研究旨在探讨拓扑异构酶Ⅰ抑制剂羟基喜树碱（HCPT）和拓扑异构酶Ⅱ抑制剂替尼泊苷（VM-26）对胃癌细胞系BGC-823增殖和凋亡的影响。
采用MTT法检测VM-26和HCPT单独及联合应用对BGC-823细胞增殖的抑制作用。通过流式细胞术（FCM）检测细胞凋亡情况。
用1.963～31.413μmol/L VM-26处理时，BGC-823细胞增殖抑制率为15.99%～80.83%；用1.963μmol/L VM-26分别处理0、12、24、48 h时，细胞凋亡率分别为3.90%、4.42%、7.36%、17.07%。用8.577～137.227μmol/L HCPT处理时，BGC-823细胞增殖抑制率为7.89%～70.32%；用8.577μmol/L HCPT分别处理0、12、24、48 h时，细胞凋亡率分别为2.80%、8.50%、10.50%、13.30%。用1.963μmol/L VM-26和3.125μg/ml HCPT分别处理0、12、24、48 h时，BGC-823细胞增殖抑制率为21.32%～87.74%，细胞凋亡率分别为2.80%、15.50%、15.70%、20.20%。联合指数（CI）为1.293。
HCPT和VM-26单独使用均可抑制BGC-823细胞增殖并诱导其凋亡，二者对胃癌BGC-823细胞具有拮抗作用。
